Finasteride induced depression: A prospective study

BMC Clinical Pharmacology

Volumn 6, Issue , 2006, Pages

  Rahimi Ardabili, Babak ^a   Pourandarjani, Ramin ^b   Habibollahi, Peiman ^c   Mualeki, Amir ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE;

ADULT; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG INDUCED DISEASE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MALE TYPE ALOPECIA; PROSPECTIVE STUDY; QUESTIONNAIRE;

ADULT; ALOPECIA; ANXIETY; DEPRESSION; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSPECTIVE STUDIES; QUESTIONNAIRES;

EID: 33750592723     PISSN: 14726904     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-6-7     Document Type: Article

References (42)

1. Patten SB, Barbui C: Drug induced depression: a systemic review to inform clinical practice. Psychother Psychosom 2004, 73(4):207-215.
2. Rapaport MH, Clary C, Fayyad R, Endicott J: Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 2005, 162:1171-1178.
3. Sinclair R: Male pattern androgenic alopecia. BMJ 1998, 317:865-869.
4. Cilotti A, Danza G, Serio M: Clinical application of 5alpha-reductase inhibitors. J Endocrinol Invest 2001, 24:199-203.
5. Bienová M, Kucerová R. Fiurásková M, Hajdúch M, Koláà Z: Androgenetic alopecia and current methods of treatment. Acta Dermatovenerol Alp Panonica Adriat 2005, 14:5-8.
6. Stern RI, Heymann WR: Androgenetic alopecia. Clin Dermatol 1997, 2(32):1-6.
7. Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E, Shupack J, Stough D, DeVillez R, Rietschel R, Savin R, Bergfeld W, Swinehart J, Funicella T, Hordinsky M, Lowe N, Katz I, Lucky A, Drake L, Price VH, Weiss D, Whitmore E, Millikan L, Muller S. Gencheff C, et al.: Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol 1999, 41:555-563.
8. Oh BR, Kim SJ, Moon JD, Kim HN, Kwon DD, Won YH, Ryu SB, Park YI: Association of Benign prostate hyperplasia with male pattern baldness. Urology 1998, 51:744-748.
9. Stoffell-Wagner B: Neurosteroid metabolism in the human brain. Eur J Endocrinol 2001, 145:669-679.
10. Martini L, Melcangi RC: Androgen metabolism in the brain. J Steroid Biochem Mol Biol 1991, 39:819-828.
11. Joëls M: Steroid hormones and excitability in the mammalian brain. Front Neuroendocrinol 1997, 18:2-48.
12. McEwen BS: Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci 1991, 12:141-147.
13. Lephart ED, Ladle DR, Jacobson NA, Rhees RW: Inhibition of brain 5 alpha-reductase in pregnant rats: effects on enzymatic and behavioral activity. Brain Res 1996, 739(1-2):356-360.
14. Lephart ED: Age-related changes in brain and pituitary 5 alpha-reductase with finasteride (Proscar) treatment. Neurobiol Aging 1995, 16(4):647-650.
15. Altomare G, Capella GL: Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol 2002, 29(10):665-669.
16. Montazeri A, Vahdaninia M, Ebrahimi M, Jarvandi S: The Hospital Anxiety and Depression Scale (HADS): translation and validation study of the Iranian version. Health Qual Life Outcomes 2003, 1:14.
17. Snaith RP: The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes 2003, 1:29.
18. Eicheler W, Tuohimaa P, Vilja P, Adermann K, Forssmann WG, Aumüller G: Immunocytochemical localization of human 5 alpha-reductase 2 with polyclonal antibodies in androgen target and non-target human tissues. J Histochem Cytochem 1994, 42(5):667-675.
19. Silver RI, Wiley EL, Thigpen AE, Guileyardo JM, McConnell JD, Russell DW: Cell type specific expression of steroid 5 alpha-reductase 2. J Urol 1994, 152:438-442.
20. Ramirez VD, Zheng J: Membrane sex-steroid receptors in the brain. Front Neuroendocrinol 1996, 17:402-439.
21. Poletti A, Cascavella A, Negri-Cesi P, Colciago A, Celotti F, Martini L: 5alpha-reductase isozymes in the central nervous system. Steroids 1998, 63:246-251.
22. Paul SM, Purdy RH: Neuroactive steroids. FASEB J 1992, 6:2311-2322.
23. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM: Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986, 232:1004-1007.
24. Bitran D, Shiekh M, McLeod M: Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol 1995, 7:171-177.
25. Romeo E, Ströhle A, Spalletta G, di Michele F, Hermann B, Holsboer F, Pasini A, Rupprecht R: Effects of Antidepressant Treatment on Neuroactive Steroids in Major Depression. Am J Psychiatry 1998, 155:910-913.
26. van Broekhoven F, Verkes RJ: Neurosteroids in depression: a review. Psychopharmacology 2003, 165:97-110.
27. Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, Nguyen HH, Moore EC, Tanaka WK: The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994, 79(3):703-706.
28. Hammond GL, Hirvonen J, Vihko R: Progesterone, androstenedione, testosterone, 5 alpha-dihydrotestosterone and androsterone concentrations in specific regions of the human brain. J Steroid Biochem 1983, 18:185-189.
29. Barrett-Connor E, Von Mühlen DG, Kritz-Silverstein D: Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999, 84:573-577.
30. Frye CA, Wawrzycki J: Effect of prenatal stress and gonadal hormone condition on depressive behaviors of female and male rats. Horm Behav 2003, 44:319-326.
31. Kokate TG, Banks MK, Magee T, Yamaguchi S, Rogawski MA: Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther 1999, 288:679-684.
32. Lephart ED, Husmann DA: Altered brain and pituitary androgen metabolism by prenatal, perinatal or pre- and postnatal finasteride, flutamide or dihydrotestosterone treatment in juvenile male rats. Prog Neuropsychopharmacol Biol Psychiatry 1993, 17:991-1003.
33. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A: Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998, 95:3239-3244.
34. Steckelbroeck S. Watzka M, Reichelt R, Hans VH, Stoffel-Wagner B, Heidrich DD, Schramm J, Bidlingmaier F, Klingmüller D: Characterization of the 5alpha-Reductase-3alpha-Hydroxysteroid Dehydrogenase Complex in the Human Brain. J Clin Endocrinol Metab 2001, 86(3):1324-1331.
35. Stoffel-Wagner B, Beyenburg S, Watzka M, BluÉmcke I, Bauer J, Schramm J, Bidlingmaier F, Elger CE: Expression of 5α-reductase and 3α-hydroxysteroid oxidoreductase in the hippocampus of patients with chronic temporal lobe epilepsy. Epilepsia 2000, 41:140-147.
36. Harris G, Azzolina B, Baginsky W, Cimis G, Rasmusson GH, Tolman RL, Raetz CR, Ellsworth K: Identification and selective inhibition of an isozyme of steroid 5 alpha-reductase in human scalp. Proc Natl Acad Sci USA 1992, 89:10787-10791.
37. Herzog AG, Frye CA: Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol 2003, 53:390-391.
38. Reddy DS, O'Malley BW, Rogawski MA: Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology 2005, 48:14-24.
39. Brot MD, Akwa Y, Purdy RH, Koob GF, Britton KT: The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors. Eur J Pharmacol 1997, 325:1-7.
40. Edinger KL, Frye CA: Testosterone's anti-anxiety and analgesic effects may be due in part to actions of its 5alpha-reduced metabolites in the hippocampus. Psychoneuroendacrinology 2005, 30(5):418-430.
41. Arca E, Açikgöz G, Taitan HB, Köse O, Kurumlu Z: An Open, Randomized, Comparative Study of Oral Finasteride and 5% Topical Minoxidil in Male Androgenetic Alopecia. Dermatology 2004, 209:117-125.
42. Mantzoros CS, Georgiadis EI, Trichopoulos D: Contribution of dihydrotestosterone to male sexual behaviour. BMJ 1995, 310:1289-1291.